FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904508904> ?p ?o ?g. }

• W2904508904 endingPage "1067" @default.
• W2904508904 startingPage "1061" @default.
• W2904508904 abstract "Purpose Limited pelvic nodal relapse of prostatic cancer is a paramount challenge for locoregional salvage treatments. Salvage whole pelvis radiation therapy as considered in the BLINDED trial is an attractive option, but there are concerns about its toxicity. This article describes early toxicity with the technique. Methods and Materials BLINDED was a prospective multicenter phase 2 trial investigating high-dose salvage pelvic irradiation with an additional dose to the fluorocholine-based positron emission tomography–positive pelvic lymph nodes, combined with 6-month androgen blockade. The prescribed dose was 54 Gy in 1.8 Gy fractions with up to 66 Gy in 2.2 Gy fractions to the pathologic pelvic lymph nodes. Early toxicity was defined as toxicity until 1 year after radiation therapy. Patients quality of life was assessed using the European Organisation for Research and Treatment of Cancer questionnaires (QLQ-C30 and QLQ-PR25). Results Seventy-four patients were recruited in 15 French radiation oncology departments between August 2014 and July 2016. Seven were excluded before treatment because of violation of the inclusion criteria. The intention-to-treat analysis therefore included 67 patients. Half had received prior prostatic irradiation. Median age was 67.7 ± 6.5 years. Grade 2 acute urinary toxicity was observed in 9 of 67 patients (13.4%), and grade 2 1-year toxicity occurred in 4 of 67 patients (6%). Three patients (4.4%) had grade 3 urinary toxicity. Grade 2 acute digestive toxicity was observed in 10 of 67 patients (14.9%), and grade 2 1-year toxicity occurred in 4 of 67 patients (6%). Patients with prior prostate bed irradiation did not exhibit increased urinary or digestive toxicity. The European Organisation for Research and Treatment of Cancer questionnaire scores at 1 year did not worsen significantly. Conclusions The acute and 1-year toxicity of the BLINDED protocol was satisfactory, even in patients with a history of prostatic irradiation. Limited pelvic nodal relapse of prostatic cancer is a paramount challenge for locoregional salvage treatments. Salvage whole pelvis radiation therapy as considered in the BLINDED trial is an attractive option, but there are concerns about its toxicity. This article describes early toxicity with the technique. BLINDED was a prospective multicenter phase 2 trial investigating high-dose salvage pelvic irradiation with an additional dose to the fluorocholine-based positron emission tomography–positive pelvic lymph nodes, combined with 6-month androgen blockade. The prescribed dose was 54 Gy in 1.8 Gy fractions with up to 66 Gy in 2.2 Gy fractions to the pathologic pelvic lymph nodes. Early toxicity was defined as toxicity until 1 year after radiation therapy. Patients quality of life was assessed using the European Organisation for Research and Treatment of Cancer questionnaires (QLQ-C30 and QLQ-PR25). Seventy-four patients were recruited in 15 French radiation oncology departments between August 2014 and July 2016. Seven were excluded before treatment because of violation of the inclusion criteria. The intention-to-treat analysis therefore included 67 patients. Half had received prior prostatic irradiation. Median age was 67.7 ± 6.5 years. Grade 2 acute urinary toxicity was observed in 9 of 67 patients (13.4%), and grade 2 1-year toxicity occurred in 4 of 67 patients (6%). Three patients (4.4%) had grade 3 urinary toxicity. Grade 2 acute digestive toxicity was observed in 10 of 67 patients (14.9%), and grade 2 1-year toxicity occurred in 4 of 67 patients (6%). Patients with prior prostate bed irradiation did not exhibit increased urinary or digestive toxicity. The European Organisation for Research and Treatment of Cancer questionnaire scores at 1 year did not worsen significantly. The acute and 1-year toxicity of the BLINDED protocol was satisfactory, even in patients with a history of prostatic irradiation." @default.
• W2904508904 created "2018-12-22" @default.
• W2904508904 creator A5001022411 @default.
• W2904508904 creator A5012051564 @default.
• W2904508904 creator A5019810674 @default.
• W2904508904 creator A5023740879 @default.
• W2904508904 creator A5027911519 @default.
• W2904508904 creator A5029189610 @default.
• W2904508904 creator A5043943071 @default.
• W2904508904 creator A5044502328 @default.
• W2904508904 creator A5045225041 @default.
• W2904508904 creator A5046909112 @default.
• W2904508904 creator A5049756209 @default.
• W2904508904 creator A5049855178 @default.
• W2904508904 creator A5050184458 @default.
• W2904508904 creator A5054669965 @default.
• W2904508904 creator A5058513387 @default.
• W2904508904 creator A5073583906 @default.
• W2904508904 creator A5079801798 @default.
• W2904508904 creator A5079924520 @default.
• W2904508904 creator A5091210921 @default.
• W2904508904 date "2019-04-01" @default.
• W2904508904 modified "2023-10-12" @default.
• W2904508904 title "Early Toxicity of a Phase 2 Trial of Combined Salvage Radiation Therapy and Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS GETUG P07)" @default.
• W2904508904 cites W2041543289 @default.
• W2904508904 cites W2069529150 @default.
• W2904508904 cites W2094870141 @default.
• W2904508904 cites W2101472796 @default.
• W2904508904 cites W2113394230 @default.
• W2904508904 cites W2127240958 @default.
• W2904508904 cites W2137314791 @default.
• W2904508904 cites W2165631314 @default.
• W2904508904 cites W2169917633 @default.
• W2904508904 cites W2192549315 @default.
• W2904508904 cites W2338011264 @default.
• W2904508904 cites W2396402508 @default.
• W2904508904 cites W2529888262 @default.
• W2904508904 cites W2555296848 @default.
• W2904508904 cites W2740762562 @default.
• W2904508904 cites W2750662192 @default.
• W2904508904 cites W2775321189 @default.
• W2904508904 doi "https://doi.org/10.1016/j.ijrobp.2018.12.020" @default.
• W2904508904 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30557672" @default.
• W2904508904 hasPublicationYear "2019" @default.
• W2904508904 type Work @default.
• W2904508904 sameAs 2904508904 @default.
• W2904508904 citedByCount "28" @default.
• W2904508904 countsByYear W29045089042019 @default.
• W2904508904 countsByYear W29045089042020 @default.
• W2904508904 countsByYear W29045089042021 @default.
• W2904508904 countsByYear W29045089042022 @default.
• W2904508904 countsByYear W29045089042023 @default.
• W2904508904 crossrefType "journal-article" @default.
• W2904508904 hasAuthorship W2904508904A5001022411 @default.
• W2904508904 hasAuthorship W2904508904A5012051564 @default.
• W2904508904 hasAuthorship W2904508904A5019810674 @default.
• W2904508904 hasAuthorship W2904508904A5023740879 @default.
• W2904508904 hasAuthorship W2904508904A5027911519 @default.
• W2904508904 hasAuthorship W2904508904A5029189610 @default.
• W2904508904 hasAuthorship W2904508904A5043943071 @default.
• W2904508904 hasAuthorship W2904508904A5044502328 @default.
• W2904508904 hasAuthorship W2904508904A5045225041 @default.
• W2904508904 hasAuthorship W2904508904A5046909112 @default.
• W2904508904 hasAuthorship W2904508904A5049756209 @default.
• W2904508904 hasAuthorship W2904508904A5049855178 @default.
• W2904508904 hasAuthorship W2904508904A5050184458 @default.
• W2904508904 hasAuthorship W2904508904A5054669965 @default.
• W2904508904 hasAuthorship W2904508904A5058513387 @default.
• W2904508904 hasAuthorship W2904508904A5073583906 @default.
• W2904508904 hasAuthorship W2904508904A5079801798 @default.
• W2904508904 hasAuthorship W2904508904A5079924520 @default.
• W2904508904 hasAuthorship W2904508904A5091210921 @default.
• W2904508904 hasBestOaLocation W29045089041 @default.
• W2904508904 hasConcept C116263406 @default.
• W2904508904 hasConcept C121608353 @default.
• W2904508904 hasConcept C126322002 @default.
• W2904508904 hasConcept C126894567 @default.
• W2904508904 hasConcept C141071460 @default.
• W2904508904 hasConcept C143998085 @default.
• W2904508904 hasConcept C2776694085 @default.
• W2904508904 hasConcept C2780192828 @default.
• W2904508904 hasConcept C2780775027 @default.
• W2904508904 hasConcept C2780849966 @default.
• W2904508904 hasConcept C29730261 @default.
• W2904508904 hasConcept C509974204 @default.
• W2904508904 hasConcept C71924100 @default.
• W2904508904 hasConcept C77411442 @default.
• W2904508904 hasConceptScore W2904508904C116263406 @default.
• W2904508904 hasConceptScore W2904508904C121608353 @default.
• W2904508904 hasConceptScore W2904508904C126322002 @default.
• W2904508904 hasConceptScore W2904508904C126894567 @default.
• W2904508904 hasConceptScore W2904508904C141071460 @default.
• W2904508904 hasConceptScore W2904508904C143998085 @default.
• W2904508904 hasConceptScore W2904508904C2776694085 @default.
• W2904508904 hasConceptScore W2904508904C2780192828 @default.
• W2904508904 hasConceptScore W2904508904C2780775027 @default.
• W2904508904 hasConceptScore W2904508904C2780849966 @default.
• W2904508904 hasConceptScore W2904508904C29730261 @default.

• next